

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over ID6407**

**Provisional Stakeholder List**

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Servier Laboratories (vorasidenib)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Astro Brain Tumour Fund</li> <li>• Beacon</li> <li>• Black Health Agency for Equality</li> <li>• Brain and Spine Foundation</li> <li>• Brain Tumour Charity</li> <li>• Brainstrust</li> <li>• Cancer 52</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Childhood Cancer Patients Alliance</li> <li>• Children with Cancer</li> <li>• Headcase Cancer Trust</li> <li>• Independent Cancer Patients Voice</li> <li>• International Brain Tumour Alliance</li> <li>• Macmillan Cancer Support</li> <li>• Maggie’s Centres</li> <li>• Marie Curie</li> <li>• Neurological Alliance</li> <li>• Solving Kids Cancer</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Teenage Cancer Trust</li> <li>• Tenovus Cancer Care</li> <li>• The Brain Charity</li> <li>• Young Lives vs Cancer</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of British Neurologists</li> <li>• Association of Cancer Physicians</li> <li>• Association of Surgeons of Great Britain and Ireland</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health - Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Government</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Andrew McCartney Trust Fund for Brain Tumour Research</li> <li>• Brain Tumour Research</li> <li>• Brain Tumour Research Campaign</li> <li>• Cochrane Childhood Cancer Group</li> <li>• Genomics England</li> <li>• Institute of Cancer Research</li> <li>• Institute of Neurology, UCL</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Oracle Cancer Trust</li> </ul>

Provisional stakeholder list for the evaluation of vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over ID6407

Issue date: September 2024

© National Institute for Health and Care Excellence 2024. All rights reserved.

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• British Association of Surgical Oncology</li> <li>• British Geriatrics Society</li> <li>• British Institute of Radiology</li> <li>• British Neuro-Oncology Society</li> <li>• British Oncology Pharmacy Association</li> <li>• British Psychosocial Oncology Society</li> <li>• British Skull Base Society</li> <li>• Cancer Research UK</li> <li>• Children’s Cancer &amp; Leukaemia Group</li> <li>• National Neuroscience Advisory Group</li> <li>• Neonatal and Paediatric Pharmacists Group</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Paediatrics and Child Health</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• Society of British Neurological Surgeons</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.